Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 55Sarcoma 5Other hematologic neoplasm 2Classical hematology 2Genitourinary 1Dermatologic 1

Conditions

Melanoma 3134Skin Neoplasms 553Lymphoma, T-Cell, Cutaneous 543Carcinoma, Non-Small-Cell Lung 421Neoplasms 388Mycosis Fungoides 369Breast Neoplasms 364Carcinoma, Basal Cell 359Keratosis, Actinic 335Sezary Syndrome 331Lymphoma, Non-Hodgkin 312Carcinoma, Renal Cell 308Neoplasm Metastasis 304Lymphoma 299Leukemia, Lymphocytic, Chronic, B-Cell 292Lymphoma, Large B-Cell, Diffuse 287Lymphoma, Follicular 286Hodgkin Disease 275Uveal Melanoma 274Lymphoma, B-Cell, Marginal Zone 273Lymphoma, Mantle-Cell 272Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Burkitt Lymphoma 258Lymphoma, Large-Cell, Immunoblastic 248Lung Neoplasms 236Colorectal Neoplasms 232Ovarian Neoplasms 214Lymphoma, Large-Cell, Anaplastic 206Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 203Multiple Myeloma 199

Interventions

mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatoses × Dermatologic × Clear all
NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Sutter Health

Phase 2 Recruiting
10 enrolled
CNSDermatologic

Melanoma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡